Nela Vanova

Nela Vanova

Auto-generated profile, based on publicly available information

Nela Vanova

Department of Pharmaceutical Chemistry and Pharmaceutical Analysis Faculty of Pharmacy in Hradec Kralove Charles University Akademika Heyrovskeho 1203 Hradec Kralove 500 05 Czech Republic

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2018 in Journal of Applied Toxicology
Verified
Journal Article
Closed access
PDF file
NVNela Vanova
Nela Vanova
JPJaroslav Pejchal
Jaroslav Pejchal
DHDavid Herman
David Herman
ADAlzbeta Dlabkova
Alzbeta Dlabkova
DJDaniel Jun
Daniel Jun

9 February 2018 in Drug and Chemical Toxicology
Verified
Journal Article
Closed access
LMLubica Muckova
Lubica Muckova
JPJaroslav Pejchal
Jaroslav Pejchal
PJPetr Jost
Petr Jost
NVNela Vanova
Nela Vanova
DHDavid Herman
David Herman
DJDaniel Jun
Daniel Jun
The development of acetylcholinesterase reactivators, i.e., antidotes against organophosphorus poisoning, is an important goal of defense research. The aim of this study was to compare cytotoxicity and chemical structure of five currently available oximes (pralidoxime, trimedoxime, obidoxime, methoxime, and asoxime) together with four perspective oximes from K-series (K027, K074, K075, and K203). The cytotoxicity of tested substances was measured using two methods – colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide assay and impedance based real-time cytotoxicity assay – in three different cell lines (HepG2, ACHN, and NHLF). Toxicity was subsequently expressed as toxicological index IC50. The tested compounds showed different cytotoxicity ranging from 0.92 to 40.06 mM. In HepG2 cells, K027 was the least and asoxime was the most toxic reactivator. In ACHN and NHLF cell lines, trimedoxime was the compound with the lowest adverse effects, whereas the highest toxicity was found in methoxime-treated cells. The results show that at least five structural features affect the reactivators’ toxicity such as the number of oxime groups in the molecule, their position on pyridinium ring, the length of carbon linker, and the oxygen substitution or insertion of the double bond into the connection chain. Newly synthetized oximes with IC50 ≥ 1 mM evaluated in this three cell lines model might appear suitable for further testing.

21 August 2018 in Biomedical Chromatography
Verified
Journal Article
Closed access
PDF file
NVNela Vanova
Nela Vanova
LMLubica Muckova
Lubica Muckova
MSMonika Schmidt
Monika Schmidt
DHDavid Herman
David Herman
ADAlzbeta Dlabkova
Alzbeta Dlabkova
DJDaniel Jun
Daniel Jun

30 November 2019 in Drug Testing and Analysis
Verified
Journal Article
Closed access
PDF file
DHDavid Herman
David Herman
ADAlzbeta Dlabkova
Alzbeta Dlabkova
LCLenka Cechova
Lenka Cechova
NVNela Vanova
Nela Vanova
JMJan Misik
Jan Misik
JKJana Zdarova Karasova
Jana Zdarova Karasova

22 November 2024 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
DPDawid Panek
Dawid Panek
APAnna Pasieka
Anna Pasieka
JJJakub Jończyk
Jakub Jończyk
MGMilena Gawlińska
Milena Gawlińska
PZPaula Zaręba
Paula Zaręba
Barbara MalawskaBarbara Malawska
Barbara Malawska
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss and behavioral and psychological symptoms of dementia (BPSD). Given that cholinergic neurons are predominantly affected in AD, current treatments primarily aim to enhance cholinergic neurotransmission. However, imbalances in other neurotransmitters, such as γ‐aminobutyric acid (GABA), also contribute to AD symptomatology. In the presented research, using a combination of crystallography and computational methods we developed compound 6 as a dual modulator of GABAergic and cholinergic neurotransmission systems. Compound 6 demonstrated inhibition of BuChE (IC50=0.21 μM) and GABA transporter 1 (IC50=10.96 μM) and 3 (IC50=7.76 μM), along with a favorable drug‐likeness profile. Subsequent in vivo studies revealed the effectiveness of 6 in enhancing memory retention and alleviating anxiety and depression symptoms in animal models, while also proving safe and bioavailable for oral administration. The innovative multi‐target‐directed ligand 6 offers a new approach to treating cognitive deficits and BPSD in AD.

1 April 2021 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
NVNela Vanova
Nela Vanova
AHAnna Hojna
Anna Hojna
JPJaroslav Pejchal
Jaroslav Pejchal
DHDavid Herman
David Herman
DMDavid Malinak
David Malinak
JKJana Zdarova Karasova
Jana Zdarova Karasova